We’re pleased to announce our second public release of 2015 (version 2015.2) where we have introduced the new features and content updates listed below (and detailed on our download pages) with the objective of becoming more “consumable”. This is not only an invitation for subsumation into local systems via API calls but also via data downloads. Please note there are a number of good reasons to contact us early on in the course of any integration efforts, including technical assistance or optimisation where we can, as well as basic professional courtesy for us to know who is using our stuff. We realise some local instanciations will involve proprietory internal systems (e.g. pharmaceutical companies or competitive intelligence brokers) but we would simply like feedback on how the process (e.g. ETL procedures) went, without needing any disclosure of your internal architecture or content. We envisage 2015.3 to be ready by about November.
- Family summary pages have been reviewed and updated in preparation for producing the Concise Guide to PHARMACOLOGY 2015/16 due out later this year
- GPCR updates:
- Enzyme updates:
- Added inhibitors for many proteinase targets
- Mutation information, listed in the ‘Clinical mutations and Pathophysiology’ tables, has been standardised across the database. This builds upon earlier work to standardise the disease names used across the database to conform to Disease Ontology and Orphanet Rare Disease Ontology names where possible.
|Targets with ligand interactions||1505|
|Targets with quantitative ligand interactions||1228|
|Targets with approved drug interactions||554|
|Primary targets with approved drug interactions||312|
|Ligands with target interactions||6796|
|Ligands with quantitative interactions (approved drugs)||5860 (738)|
|Ligands with clinical use summaries (approved drugs)||1724 (1231)|
|Number of binding constants||44691|
|Number of binding constants curated from the literature||13484|
Table 1. Interaction counts. Primary target indicates the dominant MMOA.
The table shows a few of the main relationship statistics for the 2015.2 release. Further tables with target and ligand category breakdowns are available on the GtoPdb About page.
Figure 1. Relationship growth since 2012.
The first (left-most) chart shows the number of targets with curated ligand interactions while the second chart includes only those targets that are supported by quantitative data. The third and fourth charts show the number of approved drugs with data-supported targets and those that may be considered primary targets, respectively.